Chimeric switch receptor and use thereof
By designing chimeric conversion receptors, including extracellular domains of TIGIT and PD-1, immune cells can recognize and kill multiple tumor cells by immune cells, solve the problems of tumor heterogeneity and immune escape, and improve tumor treatment Effects and safety.
Patent Information
- Application Number
- PCT/CN2024/089865
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-12
- Filing Date
- 2024-04-25
- Publication Date
- 2024-11-21
AI Technical Summary
Traditional single chimeric antigen receptors have limited efficacy in tumor therapy and cannot effectively identify tumor cells with inconsistent expression of TIGIT or PD-1 ligands due to tumor heterogeneity and immune escape mechanisms.
Design a chimeric conversion receptor, which contains extracellular domains of TIGIT and PD-1, can recognize two antigen ligands simultaneously, activate immune cells, and realize the 'OR-gate' logical gating effect of immune cells on tumor antigens. Reverse inhibitory signals and avoid immune depletion.
It significantly improves the tumor killing activity and therapeutic effect of immune cells, reduces the depletion state of immune cells, overcomes the problems of tumor immune escape and antigen heterogeneity, and improves the efficacy and safety of tumor treatment.
Smart Images

Figure PCTCN2024089865-FTAPPB-I100001 
Figure PCTCN2024089865-FTAPPB-I100002 
Figure PCTCN2024089865-FTAPPB-I100003
Abstract
Description
Chimeric switch receptors and their applications Technical Field
[0001] The present invention relates to the field of biopharmaceuticals, specifically, the present invention relates to a chimeric switch receptor and its application, specifically to a CSR-immune cell and its application in the field of tumor treatment, and more specifically, the present invention relates to a chimeric switch receptor that can simultaneously recognize two antigen ligands and corresponding nucleic acid molecules, expression vectors, lentiviral vectors, transgenic immune cells, pharmaceutical compositions and their uses. Background Art
[0002] Chimeric switch receptor (CSR) is an artificially constructed recombinant receptor that contains an extracellular antigen recognition domain, a transmembrane region, and an intracellular signal transduction domain. Unlike the extracellular antigen recognition domain of the chimeric antigen receptor, which is composed of a single-chain antibody, the extracellular antigen recognition domain of the chimeric switch receptor is mainly composed of inhibitory surface receptors of immune cells. The chimeric switch receptor recognizes the ligands of the inhibitory receptor, thereby converting the original immunosuppressive signal into an immune activation signal, activating immune cells and triggering an immune response against target cells expressing inhibitory receptor ligands. Immune cell therapy based on chimeric switch receptors is an emerging direction in the field of tumor treatment.
[0003] Chimeric switch receptor immune cell therapy has good application prospects in tumor treatment, but its efficacy still needs to be further improved.
[0004] Summary of the Invention
[0005] The present invention aims to solve at least one of the technical problems existing in the prior art to a certain extent. To this end, the present invention provides a chimeric switch receptor that can simultaneously recognize the ligand antigens of two immune receptors. The chimeric switch receptor of the present invention can simultaneously recognize the ligand antigens of two immune receptors. The immune cells expressing the chimeric switch receptor can be activated after recognizing any one of the ligand antigens of the two immune receptors, thereby realizing the "OR gate" logical gating effect of immune cell recognition of tumor antigens, solving the problems of tumor immune escape and tumor antigen heterogeneity, more effectively reversing the inhibition of inhibitory signals from the tumor microenvironment, avoiding immune exhaustion of immune cells such as NK cells, and effectively improving the therapeutic effect of immune cells based on chimeric switch receptors.
[0006] It should be noted that the present invention is completed based on the following work of the inventors:
[0007] Tumors are heterogeneous. Although the ligands for the inhibitory receptor TIGIT and the inhibitory receptor PD-1 are highly expressed in tumor cells, they are often not expressed simultaneously even in the same tumor cell. For example, it is not uncommon for only some tumor cells to express one ligand and another to express the other. Furthermore, tumor escape mechanisms can also lead to the loss of TIGIT or PD-1 ligands in tumor cells. Therefore, traditional single chimeric antigen receptors or chimeric switch receptors cannot effectively recognize these ligands, and their efficacy is limited.
[0008] In order to solve the above problems, the inventors boldly proposed the following idea: to express two chimeric conversion receptors simultaneously in an immune cell (such as NK cells or T cells), and the resulting immune cells are expected to effectively recognize tumor cells in both of the above situations, thereby triggering anti-tumor effects and improving therapeutic effects. Furthermore, the inventors selected the extracellular domains of the human inhibitory receptor TIGIT and the human inhibitory receptor PD-1 as the extracellular antigen recognition domains of the chimeric conversion receptors. After a large number of bioinformatics simulations and screening tests, two TIGIT and PD-1 extracellular truncations with good binding activity to PD-L1 and CD155 were obtained.
[0009] To further improve the efficacy of immune cell therapy, the inventors cleverly connected the extracellular truncations of TIGIT and PD-1 and used them as extracellular antigen recognition domains to obtain a chimeric converting receptor that contains both antigen recognition domains.
[0010] Further experimental results showed that NK cells modified with the chimeric conversion receptor gene containing the above-mentioned TIGIT and PD-1 antigen recognition domains can recognize TIGIT ligands and PD-1 ligands at the same time, and can reverse any inhibitory signal transmitted by TIGIT or PD-1 recognizing the corresponding ligand into an activation signal, thereby avoiding the loss of function or exhaustion of NK cells in the tumor microenvironment. Further animal level experimental results showed that the above-mentioned gene-modified NK cells can effectively recognize tumor cells that partially express TIGIT ligands or partially express PD-1 ligands, and can also effectively recognize tumor cells that have lost one of the receptor ligands of PD-1 or TIGIT. In this way, the problems of tumor immune escape and tumor antigen heterogeneity are solved, and the therapeutic effect of immune cells based on chimeric conversion receptors is improved.
[0011] Therefore, in the first aspect of the present invention, the present invention proposes a chimeric conversion receptor. The chimeric conversion receptor comprises: an extracellular region, the extracellular region comprises a first binding fragment and a second binding fragment, the first binding fragment has an amino acid sequence as shown in SEQ ID NO: 10, and the second binding fragment has an amino acid sequence as shown in SEQ ID NO: 11; a transmembrane region, the N-terminus of the transmembrane region is connected to the C-terminus of the extracellular region; an intracellular region, the N-terminus of the intracellular region is connected to the C-terminus of the transmembrane region. The chimeric conversion receptor of the present invention has both PD-L1 and CD155 binding activity. Immune cells expressing the chimeric conversion receptor of the present invention can effectively recognize tumor cells that partially express TIGIT ligands or partially express PD-1 ligands, and can also effectively recognize tumor cells that have lost one of the receptor ligands of PD-1 or TIGIT.
[0012] In a second aspect, the present invention provides a nucleic acid molecule encoding the chimeric switch receptor described above. Immune cells carrying the nucleic acid molecule express the chimeric switch receptor of the first aspect of the invention. The chimeric switch receptor can activate the immune cell upon recognizing either a TIGIT ligand or a PD-1 ligand, thereby achieving an OR-like logic gating effect for immune cell recognition of tumor antigens.
[0013] In a third aspect, the present invention provides an expression vector carrying the nucleic acid molecule of the second aspect of the present invention. Thus, the chimeric switch receptor of the first aspect of the present invention can be effectively expressed in cells using the constructed expression vector.
[0014] In a fourth aspect, the present invention provides a lentiviral vector carrying a nucleotide sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 15. After the lentiviral vector of the fourth aspect of the present invention is introduced into a recipient cell, the recipient cell can express the chimeric switch receptor of the first aspect of the present invention.
[0015] In the fifth aspect of the present invention, the present invention proposes a transgenic immune cell, which expresses the chimeric conversion receptor of the first aspect of the present invention, or carries the nucleic acid molecule of the second aspect of the present invention, the expression vector of the third aspect of the present invention, or the lentiviral vector of the fourth aspect of the present invention. Thus, the transgenic immune cells obtained can be further used for tumor treatment, and have significantly improved tumor killing activity and effectively reduced immune cell exhaustion state. Clinically, it is only necessary to administer the immune cells of the present invention to effectively eliminate the drug resistance of tumor patients to therapeutic immune cells caused by immune escape and / or tumor antigen heterogeneity. At the same time, compared with the treatment regimen of administering multiple therapeutic immune cells sequentially or simultaneously to recognize different tumor cell ligands, the clinical application of the immune cells of the present invention is safer and more convenient, which is conducive to the clinical application of cell therapy.
[0016] In a sixth aspect, the present invention provides a pharmaceutical composition comprising the chimeric switch receptor of the first aspect of the present invention, the nucleic acid molecule of the second aspect of the present invention, the expression vector of the third aspect of the present invention, the lentiviral vector of the fourth aspect of the present invention, or the transgenic immune cell of the fifth aspect of the present invention. The resulting pharmaceutical composition can be further used for the prevention or treatment of tumor diseases.
[0017] In a seventh aspect, the present invention provides the use of the chimeric switch receptor of the first aspect, the nucleic acid molecule of the second aspect, the expression vector of the third aspect, the lentiviral vector of the fourth aspect, the transgenic immune cell of the fifth aspect, or the pharmaceutical composition of the sixth aspect in the preparation of a medicament for preventing or treating tumors. The chimeric switch receptor and corresponding nucleic acid molecule, expression vector, lentiviral vector, transgenic immune cell, or pharmaceutical composition of the present invention can be further prepared into a medicament, which can be clinically used to prevent or treat a disease.
[0018] Those skilled in the art will appreciate that the features and advantages described above for the chimeric switch receptor, nucleic acid molecule, expression vector, lentiviral vector, transgenic immune cell and pharmaceutical composition are also applicable to this use and will not be described in detail here.
[0019] Additional aspects and advantages of the present invention will be set forth in part in the description which follows and, in part, will be obvious from the description which follows, or may be learned by practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] The above and / or additional aspects and advantages of the present invention will become apparent and readily understood from the following description of the embodiments with reference to the accompanying drawings, in which:
[0021] FIG1 is a schematic diagram of the double (OR gate) chimeric switch receptor structure of Example 1 of the present invention;
[0022] FIG2 is a graph showing the results of investigating the in vitro cytotoxic effect of double (OR gate) chimeric switch receptor NK cells according to Example 2 of the present invention;
[0023] FIG3 is a graph showing the results of investigating the in vitro degranulation level of double (OR gate) chimeric switch receptor NK cells according to Example 3 of the present invention;
[0024] FIG4 is a graph showing the results of investigating the in vitro interferon-γ production level of double (OR gate) chimeric switch receptor NK cells according to Example 3 of the present invention;
[0025] FIG5 is a graph showing the results of investigating the expression of PD-1 and TIGIT ligands in the ovarian cancer cell line HEY according to Example 4 of the present invention;
[0026] FIG6 is a graph showing the results of investigating the killing efficiency of double (OR gate) chimeric switch receptor NK cells against ovarian cancer cells HEY according to Example 4 of the present invention;
[0027] FIG7 is a graph showing the in vivo anti-tumor effect of the dual (OR gate) chimeric switch receptor NK cells on ovarian cancer according to Example 4 of the present invention, wherein the ordinate represents the tumor volume and the abscissa represents the tumor-bearing time in lung cancer model mice;
[0028] FIG8 is a graph showing the results of investigating the killing efficiency of the double (OR gate) chimeric switch receptor NK cells against lung cancer cells NCI-H1975 according to Example 5 of the present invention;
[0029] FIG9 is a graph showing the results of investigating the killing efficiency of the double (OR gate) chimeric switch receptor NK cells against lung cancer cells HCC827 according to Example 5 of the present invention;
[0030] FIG10 is a graph showing the in vivo anti-tumor effect of the dual (OR gate) chimeric switch receptor NK cells on lung cancer according to Example 5 of the present invention, wherein the ordinate represents the tumor volume and the abscissa represents the tumor-bearing time of the lung cancer model mice;
[0031] Figure 11 is a graph showing the in vivo anti-tumor effect of the dual (OR gated) chimeric switch receptor NK cells on lung cancer according to Example 5 of the present invention, wherein the ordinate represents the tumor weight of lung cancer model mice on the 40th day after tumor bearing (NK cell treatment once a week), and the abscissa represents different experimental groups, "PBS" represents the blank control group injected with PBS solution via the tail vein, "WT" represents the experimental group injected with NK92 wild-type cells via the tail vein, and "TIGIT-PD1" represents the experimental group injected with NK92 cells transduced with the dual (OR gated) chimeric switch receptor via the tail vein;
[0032] FIG12 is a graph showing the results of investigating the killing efficiency of the double (OR gate) chimeric switch receptor NK cells against esophageal cancer cells TE-1 according to Example 6 of the present invention;
[0033] FIG13 is a graph showing the results of investigating the killing efficiency of the double (OR gate) chimeric switch receptor NK cells against esophageal cancer cells KYSE-150 according to Example 6 of the present invention;
[0034] FIG14 is a graph showing the results of investigating the killing efficiency of double (OR gate) chimeric switch receptor NK cells against cervical cancer cells Hela according to Example 7 of the present invention;
[0035] FIG15 is a graph showing the results of investigating the killing efficiency of the double (OR gate) chimeric switch receptor NK cells against colon cancer cells HCT15 according to Example 8 of the present invention. DETAILED DESCRIPTION
[0036] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be understood as limiting the present invention.
[0037] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be understood to indicate or imply relative importance or implicitly specify the number of the technical features indicated. Therefore, features defined as "first" or "second" may explicitly or implicitly include one or more of such features. Furthermore, in the description of the present invention, unless otherwise specified, "plurality" means two or more.
[0038] The endpoints of the ranges and any values disclosed herein are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values. For numerical ranges, the endpoints of each range, the endpoints of each range and individual point values, and the individual point values can be combined with each other to obtain one or more new numerical ranges, which should be considered to be specifically disclosed herein.
[0039] Terms and Definitions
[0040] In this document, the terms “include” or “comprising” are open expressions, that is, including the contents specified in the present invention, but not excluding other contents.
[0041] As used herein, the terms "optionally," "optional," or "optionally" generally mean that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
[0042] In this article, the term "logic gating" is equivalent to "Logic Gate". It is based on the chimeric antigen receptor, by designing two or more antigen recognition domains and applying the principles of logic gating such as "AND-Gate" and "OR-Gate" to achieve accurate recognition of target cells by immune cells.
[0043] In this article, the term "chimeric switch receptor," equivalent to "CSR," is an artificially constructed recombinant receptor that contains an extracellular antigen recognition domain, a transmembrane region, and an intracellular signal transduction domain. Unlike the extracellular antigen recognition domain of chimeric antigen receptors, which is composed of a single-chain antibody, the extracellular antigen recognition domain of chimeric switch receptors is primarily composed of inhibitory surface receptors on immune cells.
[0044] In this article, the term "immune cell expressing a chimeric conversion receptor" is equivalent to "CSR-immune cell", which is a genetically modified immune cell that expresses a specific chimeric conversion receptor and is further used for the prevention or treatment of a disease. In some specific cases, including but not limited to, it can be a CSR-T cell, or it can be at least one of any of the above immune cells derived from CSR-NK cells, CSR-NKT cells, CSR-γδT cells, CSR-macrophages, CSR-peripheral blood NK cells, CSR-umbilical cord blood NK cells or CSR-iPSC, and any CSR-NK cell line. In some cases, combined with the context, it is equivalent to "chimeric conversion receptor gene-modified immune cell technology" and "chimeric conversion receptor gene-modified immune cells".
[0045] In this document, the term "dual chimeric switch receptor" is equivalent to "OR-gated chimeric switch receptor" and, in some cases, in conjunction with the context, is equivalent to "the chimeric switch receptor of the present invention", "the chimeric switch receptor described above", and "the chimeric switch receptor of the first aspect of the present invention". The term "dual chimeric switch receptor immune cell" is equivalent to "OR-gated chimeric switch receptor immune cell" and, in some cases, in conjunction with the context, is equivalent to "the transgenic immune cell of the present invention", "the transgenic immune cell described above", and "the transgenic immune cell of the fifth aspect of the present invention". In this document, the dual (OR-gated) chimeric switch receptor is a novel chimeric switch receptor proposed in the present invention that can simultaneously recognize the ligands of two inhibitory receptors expressed on the surface of solid tumor or blood tumor cells and can activate immune cells when recognizing either ligand.
[0046] As used herein, the term "hinge domain," equivalent to the "spacer domain," is a small polypeptide sequence found in the structure of single-chain antibodies (scFvs) or their derivatives. Its function is to separate the scFv domain from immune cells (such as T cells). The length of the spacer sequence, and whether it is included at all, depends on factors such as the strength of downstream signaling triggered by ligand binding to a specific receptor. The efficacy of the spacer sequence will be determined through further experiments and cannot be predicted in advance.
[0047] In this article, the term "single-chain antibody" is equivalent to "single chain Fv" and "scFv", which is composed of the variable region of the immunoglobulin heavy chain (V H ) and light chain variable region (V L ) Small molecule antibodies connected by connecting peptides. The connecting peptides used to prepare scFv must be flexible enough to ensure V H and V L It can fold freely, so that the antibody binding region has the correct configuration.
[0048] In this article, the term "(G4S) n " is equivalent to "(Gly4Ser)n", which means 4 glycines and 1 serine are repeated n times. It is a widely used type of linker peptide that can be located at V H C-terminal and V L N terminal, can also be located at V L C-terminal and V H Between the N-termini, (G4S)3 is commonly used. Glycine, the amino acid with the smallest molecular weight and shortest side chain, increases side chain flexibility, while serine, the most hydrophilic amino acid, increases the hydrophilicity of the linker. Therefore, (G4S)3 exhibits excellent stability and activity. Linkers of varying lengths and sequences can be designed to construct scFvs with diverse biological functions.
[0049] In this article, the term "vector" generally refers to a nucleic acid molecule that can be inserted into a suitable host and replicates itself, and the inserted nucleic acid molecule is transferred into and / or between host cells. The vector may include a vector that is mainly used to insert DNA or RNA into a cell, a vector that is mainly used to replicate DNA or RNA, and a vector that is mainly used for expression of the transcription and / or translation of DNA or RNA. The vector also includes a vector with a variety of the above functions. The vector can be a polynucleotide that can be transcribed and translated into a polypeptide when introduced into a suitable host cell. Typically, the vector can produce a desired expression product by cultivating a suitable host cell containing the vector.
[0050] As used herein, the term "pharmaceutical composition" generally refers to a unit dosage form and can be prepared by any of the methods well known in the pharmaceutical art. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. Generally, the compositions are prepared by uniformly and thoroughly combining the active compound with a liquid carrier, a solid carrier, or both.
[0051] As used herein, the term "pharmaceutically acceptable excipient" includes any solvent, solid excipient, diluent, or other liquid excipient, etc., suitable for the particular intended dosage form. Except to the extent that any conventional excipient is incompatible with the chimeric switch receptor, nucleic acid molecule, expression vector, lentiviral vector, or transgenic immune cell of the present invention, such as by producing any adverse biological effect or interacting in a deleterious manner with any other component of the pharmaceutically acceptable composition, their use is also contemplated by the present invention.
[0052] As used herein, the term "administer" refers to the introduction of a predetermined amount of a substance into a patient by some suitable means. The chimeric switch receptors, nucleic acid molecules, expression vectors, lentiviral vectors, or transgenic immune cells or pharmaceutical compositions of the present invention can be administered by any common route, as long as it can reach the desired tissue. Various modes of administration are contemplated, including peritoneal, intravenous, intramuscular, and subcutaneous administration, but the present invention is not limited to these exemplified modes of administration. Preferably, the compositions of the present invention are administered by intravenous injection.
[0053] As used herein, the term "treatment" is used to refer to obtaining a desired pharmacological and / or physiological effect. The effect may be preventative in terms of completely or partially preventing a disease or its symptoms, and / or therapeutic in terms of partially or completely curing a disease and / or adverse effects caused by the disease. "Treatment" as used herein covers diseases in mammals, particularly humans, and includes: (a) preventing the occurrence of a disease or condition in an individual who is susceptible to the disease but has not yet been diagnosed with the disease; (b) inhibiting the disease, such as arresting the progression of the disease; or (c) alleviating the disease, such as alleviating the symptoms associated with the disease. "Treatment" as used herein covers any administration of a drug or transgenic immune cell to an individual to treat, cure, alleviate, ameliorate, reduce or inhibit the individual's disease, including but not limited to administering a drug containing cells containing a chimeric conversion receptor as described herein to an individual in need.
[0054] As used herein, "carbon terminus" and "C-terminus" are synonymous; "nitrogen terminus" and "N-terminus" are synonymous.
[0055] The present invention proposes a chimeric switch receptor that can simultaneously recognize the ligand antigens of two immune receptors, as well as corresponding nucleic acid molecules, expression vectors, lentiviral vectors, transgenic immune cells, pharmaceutical compositions and uses thereof, which are described in detail below.
[0056] Chimeric switch receptor
[0057] The present invention provides a chimeric switch receptor. The chimeric switch receptor comprises: an extracellular region, the extracellular region comprising a first binding fragment and a second binding fragment, the first binding fragment having the amino acid sequence shown in SEQ ID NO: 10, and the second binding fragment having the amino acid sequence shown in SEQ ID NO: 11; a transmembrane region, the N-terminus of the transmembrane region being connected to the C-terminus of the extracellular region; and an intracellular region, the N-terminus of the intracellular region being connected to the C-terminus of the transmembrane region.
[0058] According to an embodiment of the present invention, a TIGIT extracellular truncation (having an amino acid sequence as shown in SEQ ID NO: 10) and a PD-1 extracellular truncation (having an amino acid sequence as shown in SEQ ID NO: 11) having a specific amino acid sequence have good binding activity to PD-L1 and CD155, and can simultaneously exert binding activity in the chimeric conversion receptor of the present invention. Immune cells expressing the chimeric conversion receptor of the present invention can effectively recognize tumor cells expressing TIGIT ligands or PD-1 ligands, and can also effectively recognize tumor cells that have lost one of the receptor ligands of PD-1 or TIGIT.
[0059] According to an embodiment of the present invention, the extracellular antigen recognition domain TIGIT extracellular truncation (recognizing CD155 ligand) and PD-1 extracellular truncation (recognizing PD-L1 ligand) selected by the present invention exhibit synergistic binding activity in the chimeric conversion receptor, and the immune cells constructed thereby exhibit stronger tumor cell killing activity. Compared with immune cells that only express TIGIT or PD1 chimeric conversion receptors, immune cells expressing the chimeric conversion receptor of the present invention have a stronger killing effect on tumor cells that simultaneously express TIGIT and PD1 ligands, and the expression level of the anti-tumor effector molecule IFN-γ is also significantly improved.
[0060] Beyond the inventors' expectations, according to the embodiments of the present invention, the inventors also observed that compared with the immune cells that were only transduced with TIGIT or PD1 chimeric conversion receptors, the immune cells that were transduced with the chimeric conversion receptor of the present invention had significantly increased CD107a expression levels, indicating that the level of NK cell degranulation was significantly increased, which confirmed that NK cells at this time had a stronger ability to kill tumors.
[0061] According to an embodiment of the present invention, the chimeric switch receptor may further include at least one of the following technical features:
[0062] According to an embodiment of the present invention, the C-terminus of the first binding fragment is connected to the N-terminus of the second binding fragment, or the N-terminus of the first binding fragment is connected to the C-terminus of the second binding fragment.
[0063] According to an embodiment of the present invention, the extracellular region further includes a connecting peptide. In a specific embodiment, the TIGIT extracellular truncated form and the PD-1 extracellular truncated form are connected by a connecting peptide, thereby better exerting the CD155 and PD-L1 ligand binding activity.
[0064] According to an embodiment of the present invention, the C-terminus of the first binding fragment is connected to the N-terminus of the connecting peptide, and the C-terminus of the connecting peptide is connected to the N-terminus of the second binding fragment; or the C-terminus of the second binding fragment is connected to the N-terminus of the connecting peptide, and the C-terminus of the connecting peptide is connected to the N-terminus of the first binding fragment.
[0065] According to an embodiment of the present invention, the connecting peptide is selected from at least one of (G4S)n, ESGRS GGGGSGGGGS, EGKSSGSGSESKST, EGKSSGSGSESKSTQ, GSTSGSGKSSEGKG, KESGS VSSEQ LAQFR SLD, and ESGSVSSEELAFRSLD, where n is a non-zero integer.
[0066] According to an embodiment of the present invention, the connecting peptide is selected from (G4S) n , n is any integer between 2 and 6.
[0067] According to an embodiment of the present invention, the connecting peptide is (G4S)4.
[0068] According to an embodiment of the present invention, the extracellular region does not include a hinge domain. The inventors further discovered that, unlike typical chimeric switch receptors, the chimeric switch receptor of the present invention does not contain a hinge region between the extracellular domain and the transmembrane region, such as that found in other receptors, such as the CD8a hinge region. This facilitates the binding between the chimeric switch receptor and its ligand, and the activation of the chimeric switch receptor on immune cells.
[0069] According to an embodiment of the present invention, the transmembrane region includes the transmembrane segment of the CD8a molecule.
[0070] In some optional embodiments of the present invention, the transmembrane segment of the CD8a molecule has an amino acid sequence as shown in SEQ ID NO: 12.
[0071] According to an embodiment of the present invention, the intracellular region includes a costimulatory domain and an intracellular signaling domain.
[0072] According to an embodiment of the present invention, the C-terminus of the costimulatory factor domain is connected to the N-terminus of the intracellular signaling domain.
[0073] According to an embodiment of the present invention, the costimulatory factor domain is selected from at least one of the intracellular domains of CD28, 4-1BB, 2B4, DAP10, DAP12, CD27, CD40, OX40, and ICOS.
[0074] According to an embodiment of the present invention, the costimulatory domain is the intracellular segment of the 4-1BB molecule.
[0075] In some optional embodiments of the present invention, the 4-1BB costimulatory factor domain has an amino acid sequence as shown in SEQ ID NO: 13.
[0076] According to an embodiment of the present invention, the intracellular signaling domain is the intracellular segment of the CD3ζ molecule.
[0077] In some optional embodiments of the present invention, the intracellular segment of the CD3ζ molecule has an amino acid sequence as shown in SEQ ID NO:14.
[0078] In one embodiment of the present invention, the chimeric switch receptor has the amino acid sequence shown in SEQ ID NO:16.
[0079] In one embodiment of the present invention, the chimeric switch receptor has the amino acid sequence shown in SEQ ID NO:27.
[0080] Nucleic acid molecules
[0081] The present invention provides a nucleic acid molecule encoding the aforementioned chimeric switch receptor. Immune cells carrying the nucleic acid molecule can express the aforementioned chimeric switch receptor. The chimeric switch receptor can activate the immune cell after recognizing either a TIGIT ligand or a PD-1 ligand, thereby achieving an "OR gate" logic gating effect for immune cell recognition of tumor antigens.
[0082] It should be noted that, for nucleic acid molecules mentioned herein, those skilled in the art will understand that they actually include any one or both of the complementary double strands. For convenience, although only one strand is provided in most cases herein, the other strand complementary thereto is also disclosed. In addition, the molecular sequences in the present invention include DNA or RNA forms, and disclosure of one of them implies that the other is also disclosed.
[0083] expression vector
[0084] The present invention provides an expression vector. The expression vector carries the above-mentioned nucleic acid molecule. Thus, the constructed expression vector can express the chimeric switch receptor of the present invention in a recipient cell.
[0085] When the nucleic acid molecule is linked to an expression vector, the nucleic acid molecule can be directly or indirectly linked to the control elements on the expression vector, as long as these control elements are capable of controlling the translation and expression of the nucleic acid molecule. Of course, these control elements can be directly derived from the vector itself, or they can be exogenous, that is, not derived from the vector itself. Of course, it is sufficient that the nucleic acid molecule is operably linked to the control elements. According to an embodiment of the present invention, the expression vector is a non-pathogenic viral vector.
[0086] As used herein, the term "operably linked" refers to the attachment of an exogenous gene to a vector so that control elements within the vector, such as transcriptional and translational control sequences, can function as intended to regulate the transcription and translation of the exogenous gene. Commonly used vectors include viral vectors, plasmids, and bacteriophages. Expression vectors according to certain embodiments of the present invention, upon introduction into appropriate recipient cells, can effectively express the aforementioned nucleic acid molecules under the mediation of a regulatory system, thereby enabling the in vitro production of large quantities of the protein encoded by the nucleic acid molecules.
[0087] According to an embodiment of the present invention, the non-pathogenic virus is selected from one of retrovirus, lentivirus and adenovirus-associated virus.
[0088] According to an embodiment of the present invention, the non-pathogenic virus is a lentivirus.
[0089] Lentiviral vectors
[0090] The present invention provides a lentiviral vector. The lentiviral vector carries a nucleotide sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 15. Thus, after the lentiviral vector is introduced into a recipient cell, the chimeric switch receptor of the present invention can be expressed in the immune cell.
[0091] The present invention provides a lentiviral vector. The lentiviral vector carries a nucleotide sequence as shown in SEQ ID NO: 24 or SEQ ID NO: 25. Thus, after the lentiviral vector is introduced into a recipient cell, the chimeric switch receptor of the present invention can be expressed in the immune cell.
[0092] cell
[0093] The present invention provides a transgenic immune cell. The transgenic immune cell expresses the aforementioned chimeric switch receptor; or carries the aforementioned nucleic acid molecule, expression vector, or lentiviral vector. The resulting transgenic immune cell significantly enhances its tumor cell-killing activity, effectively reducing its attrition rate during tumor treatment.
[0094] According to an embodiment of the present invention, the transgenic immune cells are selected from at least one of T cells, NK cells, NKT cells, γδT cells, macrophages, peripheral blood NK cells, umbilical cord blood NK cells or any one of the above immune cells derived from iPSCs.
[0095] According to an embodiment of the present invention, the genetically modified immune cells are selected from T cells, NK cells, NKT cells, γδT cells, macrophages, peripheral blood NK cells, umbilical cord blood NK cells, NK92 cells and iPSC or CD34 + At least one of any of the above immune cells derived from hematopoietic stem cells.
[0096] In some specific embodiments, the transgenic immune cells are selected from NK cells.
[0097] In some more specific embodiments, the transgenic immune cells are selected from any NK cell line.
[0098] The chimeric switch receptor of the present invention can be transduced into immune cells such as T, NK, NKT, γδT, macrophages, etc. through an expression vector (lentiviral vector or retroviral vector) and expressed on the surface of these immune cells.
[0099] According to an embodiment of the present invention, the transgenic immune cells of the present invention have better clinical efficacy and safety than immune cells modified with a chimeric switch receptor gene containing only TIGIT or PD-1 antigen recognition domains administered sequentially or simultaneously under equivalent dosage and the same administration method.
[0100] Pharmaceutical composition
[0101] The present invention provides a pharmaceutical composition. The pharmaceutical composition comprises the aforementioned chimeric switch receptor, the aforementioned nucleic acid molecule, the aforementioned expression vector, the aforementioned lentiviral vector, or the aforementioned transgenic immune cell. The resulting pharmaceutical composition is further used for the treatment of tumors.
[0102] According to an embodiment of the present invention, the pharmaceutical composition further comprises: a pharmaceutically acceptable excipient.
[0103] Those skilled in the art will appreciate that the features and advantages described above for the chimeric switch receptor, nucleic acid molecule, expression vector, lentiviral vector, and transgenic immune cells are also applicable to the pharmaceutical composition and will not be described in detail here.
[0104] use
[0105] The present invention provides a use of the above-mentioned chimeric switch receptor, the above-mentioned nucleic acid molecule, the above-mentioned expression vector, the above-mentioned lentiviral vector, the above-mentioned transgenic immune cell or the above-mentioned pharmaceutical composition in preparing a drug, wherein the drug is used to prevent or treat tumors.
[0106] According to an embodiment of the present invention, the tumor is a solid tumor or a hematological tumor.
[0107] According to an embodiment of the present invention, the solid tumor includes tangible tumors selected from those occurring in internal organs, including at least one of pancreatic cancer, ovarian cancer, mesothelioma, liver cancer, bile duct cancer, gastric cancer, esophageal cancer, colorectal cancer, lung cancer, head and neck cancer, cervical cancer, glioma, kidney cancer, breast cancer, prostate cancer, and melanoma.
[0108] According to an embodiment of the present invention, the solid tumor includes a tangible tumor selected from those occurring in internal organs, including at least one of pancreatic cancer, ovarian cancer, mesothelioma, liver cancer, bile duct cancer, gastric cancer, esophageal cancer, colorectal cancer, lung cancer, head and neck cancer, cervical cancer, glioma, kidney cancer, breast cancer, prostate cancer, thyroid cancer, nasopharyngeal cancer, sarcoma, melanoma and squamous cell carcinoma of the skin.
[0109] According to an embodiment of the present invention, the blood tumor includes at least one selected from acute myeloid leukemia, acute lymphocytic leukemia, B cell lymphoma, T cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, and multiple myeloma in blood cells and hematopoietic system.
[0110] According to an embodiment of the present invention, the blood tumor includes at least one selected from acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma, myelodysplastic syndrome and myeloproliferative neoplasms in blood cells and hematopoietic system.
[0111] Methods for preventing or treating tumors
[0112] The present invention provides a method for treating and / or preventing immune system diseases. According to an embodiment of the present invention, the method comprises: administering a pharmaceutically acceptable amount of the above-mentioned transgenic immune cells or the above-mentioned pharmaceutical composition to a subject.
[0113] The effective amount of the transgenic immune cells and pharmaceutical compositions described herein may vary depending on the mode of administration and the severity of the disease to be treated. The preferred effective amount can be determined by one of ordinary skill in the art based on various factors (e.g., through clinical trials). These factors include, but are not limited to, pharmacokinetic parameters of the active ingredient, such as bioavailability, metabolism, and half-life; the severity of the disease being treated, the patient's weight, the patient's immune status, and the route of administration. For example, depending on the urgency of the treatment, several divided doses may be administered daily, or the dose may be proportionally reduced.
[0114] The sequences involved in the present invention are detailed in Table 1.
[0115] Table 1: Nucleotide / amino acid sequence description
[0116] Below, the scheme of the present invention will be explained in conjunction with embodiment.It will be understood by those skilled in the art that the following examples are only used to illustrate the present invention and should not be regarded as limiting the scope of the present invention.In the embodiment, if specific technology or conditions are not indicated, the technology or conditions described in the literature in this area or the product instructions are used.The reagents or instruments used are not indicated by the manufacturer, and are all conventional products that can be obtained by commercial purchase.
[0117] In the following examples, the methods for producing lentivirus and transducing human NK cells are as follows:
[0118] Replication-defective lentiviral vectors were prepared and collected by centrifugation for transduction of human NK cells. The following briefly describes the experimental procedures for lentiviral vector preparation, collection, and concentration: 293T cells were plated in a 150 cm² cell culture dish and transfected with plasmids using Lipofectamine 3000 (Thermo Fisher, Waltham, USA) according to the manufacturer's instructions. To each dish, 47.37 μg of the lentiviral transgene plasmid, 30.8 μg of the psPAX2 plasmid, 16.58 μg of the pMD2.G plasmid, 189.48 μl of P3000, and 118.43 μl of Lipofectamine 3000 were added. After 24 hours, the supernatant was collected and centrifuged at 250g for 5 minutes (Hunan Kecheng L4-5K centrifuge) to remove the precipitate. The supernatant was then mixed with 1 / 4 volume of PEG-IT (purchased from Systems Biosciences, Palo Alto, USA) and incubated overnight at 4°C. The next day, the supernatant was centrifuged at 1500g for 30 minutes. Finally, the viral vector pellet was resuspended in 0.3 ml of serum-free DMEM medium.
[0119] Peripheral blood lymphocytes were isolated from the peripheral blood of an anonymous healthy volunteer donor by density gradient centrifugation using human peripheral blood lymphocyte separation medium (purchased from Dakoway, Shenzhen, China), and primary human NK cells were enriched using a human NK cell enrichment kit (purchased from Miltenyi, Bergisch Gladbach, Germany). Human NK cells were cultured in RPMI-1640 complete medium and stimulated with a final concentration of 1000 U / mL human IL-2 and a final concentration of 20 ng / mL human IL-21. After 48 hours of activation, 0.5 × 10 cells were plated per well in a 24-well plate. 6 NK cells were cultured in a volume of 0.3 ml complete medium containing 100 U / mL 1640. 0.3 ml of the resuspended viral supernatant and Polybrene (8 μg / ml) were added to each well. After 12 hours, 0.45 ml of the culture supernatant was aspirated and 0.85 ml of complete medium containing 100 U / mL 1640 was added. The cells were cultured for another 3 days before use for functional analysis and subsequent experiments.
[0120] The flow cytometer used in the examples of the present invention was Beckman Cytoflex (purchased from Beckman Coulter), and the flow cytometric analysis data were analyzed using Cytexpert software (Beckman Coulter).
[0121] In the following examples, the in vitro CFSE-7AAD cytotoxicity assay method is as follows:
[0122] The cytotoxic activity of OR-gated chimeric switch receptor NK cells was assessed using a 4-hour CFSE-7AAD assay. The specific steps were as follows: Target test cells were labeled with a PBS solution containing a final concentration of 5 mM CFSE for 15 minutes at 37°C. After labeling, the cells were rinsed with RPMI medium containing 10% fetal calf serum (FCS). After rinsing, the cells were resuspended in the same medium at a concentration of 1 × 10 5 / ml. After transduction, NK cells were added to the target test cell suspension at different effector-to-target cell ratios (E:T), and the cells were seeded into 96-well round-bottom plates with a total volume of 200 μl per well. The cells were cultured in a 37-degree Celsius incubator for 4 hours. After 4 hours, all the cell suspension was aspirated from each well, and 3 μl of 7AAD solution was added to each well. After being placed in the dark for 1 minute, the proportion of 7AAD-positive cells in CFSE-positive cells was detected by flow cytometry using Beckman Cytoflex (purchased from Beckman Coulter), which is the proportion of target cell death, to reflect the cytotoxicity level of NK cells.
[0123] In the following examples, the methods for detecting NK cell degranulation and interferon-γ production levels are as follows:
[0124] In this example, the ability of chimeric transduced receptor NK cells to degranulate and produce interferon-γ was assessed by co-culturing NK cells with tumor cells. The specific steps are as follows: Target test cells and transduced NK cells were seeded into 96-well round-bottom plates at an effector-to-target ratio (E:T) of 1:3. Each well had a total volume of 200 μl, and 2 μl of anti-human CD107a fluorescent antibody was added to each well. The cells were incubated in a 37°C incubator for 3 hours. After 3 hours, the entire cell suspension was aspirated from each well, labeled with anti-human CD56 fluorescent antibody, and incubated in the dark for 15 minutes. After washing, the cells were fixed and transfected with fixative and transmembrane buffer (purchased from Biolegend, San Diego, USA) according to the manufacturer's instructions. They were then labeled with anti-human interferon-γ fluorescent antibody. After washing, the proportion of CD107a and interferon-γ positive cells among CD56-positive NK cells was measured using a Beckman Cytoflex flow cytometer (purchased from Beckman Coulter). The former represents the level of NK cell degranulation.
[0125] In the following examples, there are four types of target cells used for performance testing, namely: (1) WT K562 cells, hereinafter referred to as "WT K562"; (2) K562 cells overexpressing CD155, hereinafter referred to as "155tg K562"; (3) K562 cells with knockout of CD112 and CD155 and overexpression of PDL1, hereinafter referred to as "112&155KO PDL1tg K562"; (4) K562 cells overexpressing both PDL1 and CD155, hereinafter referred to as "155&PDL1tg K562".
[0126] It should be noted that the "plasmid" and "vector" described in the following embodiments have the same meaning and can be used interchangeably.
[0127] Example 1
[0128] In this example, a vector expressing a dual (OR gate) chimeric switch receptor was constructed as follows:
[0129] The nucleotide sequence encoding the human CD8α signal peptide (amino acid sequence shown in SEQ ID NO: 9, nucleotide sequence shown in SEQ ID NO: 2) and the chimeric switch receptor (amino acid sequence shown in SEQ ID NO: 16, nucleotide sequence shown in SEQ ID NO: 15) were cloned into a lentiviral vector containing an EF-1α promoter. Through enzyme digestion, ligation, screening and amplification of the target plasmid, a lentiviral vector expressing a double (OR gate) chimeric switch receptor was obtained.
[0130] Among them, the chimeric conversion receptor has, from N-terminus to C-terminus, the sequence of the human TIGIT extracellular region, the sequence of the human PD-1 extracellular region, the sequence of the human CD8α transmembrane region, the sequence of the human 4-1BB intracellular region and the sequence of the CD3ζ molecule intracellular segment (in the following embodiments, NK cells transduced with the chimeric conversion receptor are represented by "TIGIT-PD1"); or the chimeric conversion receptor has, from N-terminus to C-terminus, the sequence of the human PD-1 extracellular region, the sequence of the TIGIT extracellular region, the sequence of the human CD8α transmembrane region, the sequence of the human 4-1BB intracellular region and the sequence of the CD3ζ molecule intracellular segment (in the following embodiments, NK cells transduced with the chimeric conversion receptor are represented by "PD1-TIGIT").
[0131] The schematic diagram of the double (OR gate) chimeric switch receptor structure of this embodiment is shown in FIG1 , and the specific sequence information is shown in Reference Table 1 .
[0132] Example 2
[0133] In this example, the inventors further investigated the killing effect of NK cells expressing the dual (OR gate) chimeric switch receptor of Example 1 on tumor cells expressing TIGIT and PD-1 ligands according to the following method:
[0134] Replication-defective lentiviral vectors were prepared and collected by centrifugation for transduction of human NK cells: 293T cells were plated in 150 cm2 cell culture dishes and transfected with plasmids using Lipofectamine 3000 (Thermo Fisher, Waltham, USA) according to the manufacturer's instructions. Four groups were divided into each group, each differing only in the lentiviral transgene plasmid: 47.37 μg of lentiviral transgene plasmids (Ctrl, TIGIT-NKR, PD1-NKR, TIGIT-PD1-NKR, PD1-TIGIT-NKR), 30.8 μg of psPAX2 plasmid, 16.58 μg of pMD2.G plasmid, 189.48 μl of P3000, and 118.43 μl of Lipofectamine 3000 were added to each dish. The supernatant was collected at 24 hours, centrifuged at 250g for 5 minutes (centrifuge was Hunan Kecheng L4-5K) to remove the precipitate, and then mixed with 1 / 4 volume of PEG-IT (purchased from Systems Biosciences, Palo Alto, USA), placed overnight at 4 degrees Celsius, and centrifuged at 1500g for 30 minutes the next day. Finally, the viral vector pellet was resuspended in 0.3ml of DMEM serum-free culture medium. Peripheral blood-derived lymphocytes were isolated from the peripheral blood of an anonymous healthy volunteer donor by density gradient centrifugation using human peripheral blood lymphocyte separation fluid (purchased from Dakota, Shenzhen, China), and primary human NK cells were obtained by enrichment using a human NK cell enrichment kit (purchased from Miltenyi, Bergisch Gladbach, Germany). Human NK cells were cultured in RPMI-1640 complete medium and stimulated with human IL-2 at a final concentration of 1000 U / mL and human IL-21 at a final concentration of 20 ng / mL. After 48 hours of activation, 0.5×10 6 NK cells were cultured in a volume of 0.3 ml complete medium containing 100 U / mL 1640. 0.3 ml of the four resuspended viral supernatants and Polybrene (8 μg / ml) were added to each well. After 12 hours, 0.45 ml of the culture supernatant was aspirated and 0.85 ml of complete medium containing 100 U / mL 1640 was added. Three to seven days after lentiviral vector transduction, transduced NK cells were harvested and used for in vitro CFSE-7AAD cytotoxicity assays.
[0135] Four target cells tested, including WT K562, 155tg K562, 112&155KO PDL1tg K562, and 155&PDL1tg K562, were labeled with PBS containing a final concentration of 5mM CFSE at 37°C for 15 minutes. After labeling, the cells were rinsed with RPMI medium containing 10% fetal calf serum (FCS). After rinsing, the cells were resuspended in the same medium at a concentration of 1×10 5 / ml. After transduction, NK cells were added to the target test cell suspension at a 1:1 effector cell to target cell ratio (E:T), and the cells were seeded into 96-well round-bottom plates with a total volume of 200 μl per well. The cells were cultured in a 37°C incubator for 4 hours. After 4 hours, the entire cell suspension was aspirated from each well, and 3 μl of 7AAD solution was added to each well. After incubation in the dark for 1 minute, the proportion of 7AAD-positive cells among CFSE-positive cells was measured by flow cytometry using a Beckman Cytoflex (purchased from Beckman Coulter). This represents the proportion of target cell death, reflecting the cytotoxicity of NK cells.
[0136] The results of the investigation are shown in Figure 2: NK cells transduced with the TIGIT chimeric switch receptor ("TIGIT") had a higher killing rate than the control group NK cells ("Ctrl") when killing TIGIT ligand-positive tumor cells ("155tg K562" or "PDL1&155tg K562"), but had no significant difference in killing rate between them and the control group NK cells when killing TIGIT ligand-negative tumor cells ("WT K562" or "112&155KO PDL1tg K562"); NK cells transduced with the PD1 chimeric switch receptor ("PD1") had a higher killing rate than the control group NK cells ("Ctrl") when killing PD1 ligand-positive tumor cells ("112&155KO PDL1tg K562", "PDL1&155tg K562"), but had no significant difference in killing rate between them and the control group NK cells when killing PD1 ligand-negative tumor cells ("WT K562" or "155tg K562”) had no significant difference in killing rate compared with the control group NK cells; while NK cells transduced with dual chimeric switch receptors (OR gated chimeric switch receptors) ("TIGIT-PD1" or "PD1-TIGIT") had higher killing rates when killing TIGIT ligand single positive ("155tg K562"), PD1 ligand single positive ("112&155KO PDL1tg K562") or TIGIT and PD1 ligand double positive ("PDL1&155tg K562") tumor cells, while had no significant difference in killing rate when killing TIGIT and PD1 ligand double negative ("WT K562") tumor cells compared with the control group. Moreover, NK cells transduced with dual (OR gated) chimeric switch receptors ("TIGIT-PD1" or "PD1-TIGIT") had higher killing rates when killing TIGIT and PD1 ligand double positive ("PDL1&155tg K562") tumor cells. K562") tumor cells, the killing rate was higher than that of NK cells transduced with TIGIT alone or PD1 alone.
[0137] The results showed that the dual (OR gate) chimeric switch receptor can recognize tumor types with heterogeneous TIGIT / PD1 ligand expression. Compared with single TIGIT or PD1 chimeric switch receptors, the OR gate can simultaneously recognize tumors with single TIGIT ligand positive, single PD1 ligand positive, and double TIGIT and PD1 ligand positive. It can also respond to the situation where the ligand expression of one receptor is lost while the ligand of the other receptor still remains expressed, and kill the tumors.
[0138] Example 3
[0139] In this example, the inventors further investigated the degranulation and interferon gamma production levels of NK cells expressing the dual (OR gate) chimeric switch receptor of Example 1 when stimulated by tumor cells expressing TIGIT and PD-1 ligands according to the following method:
[0140] Replication-defective lentiviral vectors were prepared and collected by centrifugation for transduction of human cells. 293T cells were plated in 150-cm2 cell culture dishes and transfected with plasmids using Lipofectamine 3000 (Thermo Fisher, Waltham, USA) according to the manufacturer's instructions. The cells were divided into four groups, each differing only in the lentiviral transgene plasmids. Each dish contained 47.37 μg of lentiviral transgene plasmids (Ctrl, TIGIT-NKR, PD1-NKR, TIGIT-PD1-NKR, and PD1-TIGIT-NKR), 30.8 μg of psPAX2 plasmid, 16.58 μg of pMD2.G plasmid, 189.48 μl of P3000, and 118.43 μl of Lipofectamine 3000. The supernatant was collected at 24 hours, centrifuged at 250g for 5 minutes (centrifuge was Hunan Kecheng L4-5K) to remove the precipitate, and then mixed with 1 / 4 volume of PEG-IT (purchased from Systems Biosciences, Palo Alto, USA), placed overnight at 4 degrees Celsius, and centrifuged at 1500g for 30 minutes the next day. Finally, the viral vector pellet was resuspended in 0.3ml of DMEM serum-free culture medium. Peripheral blood-derived lymphocytes were isolated from the peripheral blood of an anonymous healthy volunteer donor by density gradient centrifugation using human peripheral blood lymphocyte separation fluid (purchased from Dakota, Shenzhen, China), and primary human NK cells were obtained by enrichment using a human NK cell enrichment kit (purchased from Miltenyi, Bergisch Gladbach, Germany). Human NK cells were cultured in RPMI-1640 complete medium and stimulated with human IL-2 at a final concentration of 1000 U / mL and human IL-21 at a final concentration of 20 ng / mL. After 48 hours of activation, 0.5×10 6 NK cells were cultured in a volume of 0.3 ml complete medium containing 100 U / mL 1640. 0.3 ml of the resuspended viral supernatant and Polybrene (8 μg / ml) were added to each well. After 12 hours, 0.45 ml of the culture supernatant was aspirated and 0.85 ml of complete medium containing 100 U / mL 1640 was added. Three to seven days after lentiviral transduction, the transduced NK cells were harvested and used for in vitro tumor cell-stimulated degranulation and interferon-γ production assays.
[0141] The experiment set up 4 target cell experimental groups, including WT K562, 155tg K562, 112&155KO PDL1tg K562, 155&PDL1tg K562, and a "no target cell" group ("NT"), for a total of 5 experimental groups.
[0142] The target cells and transduced NK cells were seeded into 96-well round-bottom plates at an effector-to-target ratio (E:T) of 1:4. Each well contained a total volume of 200 μl, and 2 μl of anti-human CD107a fluorescent antibody was added. The cells were incubated at 37°C for 3 hours. After 3 hours, the cell suspension was aspirated from each well and labeled with anti-human CD56 fluorescent antibody. After incubation in the dark for 15 minutes, the cells were washed and fixed and permeabilized using fixative and transmembrane buffer (purchased from Biolegend, San Diego, USA) according to the manufacturer's instructions. The cells were then labeled with anti-human interferon-γ fluorescent antibody. After washing, the proportion of CD107a and interferon-γ-positive cells among CD56-positive NK cells was measured using a Beckman Cytoflex flow cytometer (purchased from Beckman Coulter). The proportion of CD107a-positive cells, which represents the level of NK cell degranulation, was determined using the Beckman Cytoflex flow cytometer.
[0143] The results of the investigation are shown in Figures 3 and 4: NK cells transduced with the TIGIT chimeric switch receptor ("TIGIT") produced higher levels of IFN-γ and expressed CD107a than the control group NK cells ("Ctrl") when co-cultured with TIGIT ligand-positive tumor cells ("155tg K562" or "PDL1&155tg K562"), but had no significant difference in the levels of IFN-γ and CD107a compared with the control group NK cells when co-cultured with TIGIT ligand-negative tumor cells ("WT K562" or "112&155KO PDL1tg K562"); NK cells transduced with the PD1 chimeric switch receptor ("PD1") produced higher levels of IFN-γ and expressed CD107a than the control group NK cells ("Ctrl"). K562"), the levels of IFN-γ and CD107a expression were higher than those of the control group NK cells ("Ctrl"), but the levels of IFN-γ and CD107a expression were not significantly different from those of the control group NK cells when co-cultured with PD1 ligand-negative tumor cells ("WT K562" or "155tg K562"). However, the levels of IFN-γ and CD107a expression were not significantly different from those of the control group NK cells when co-cultured with PD1 ligand-negative tumor cells ("WT K562" or "155tg K562"). In contrast, the levels of IFN-γ and CD107a expression of NK cells transduced with dual (OR gate) chimeric switch receptors ("TIGIT-PD1" or "PD1-TIGIT") were higher than those of the control group when co-cultured with TIGIT ligand-single-positive ("155tg K562"), PD1 ligand-single-positive ("112&155KO PDL1tg K562"), or TIGIT and PD1 ligand-double-positive ("PDL1&155tg K562") tumor cells, but were not significantly different from those of the control group NK cells when co-cultured with TIGIT and PD1 ligand-double-negative ("WT K562"), the levels of IFN-γ and CD107a expression when co-cultured with tumor cells transduced with dual (OR gated) chimeric switch receptors were not significantly different from those in the control group. Moreover, the levels of IFN-γ and CD107a expression when co-cultured with tumor cells double-positive for TIGIT and PD1 ligand ("PDL1&155tg K562") were significantly higher than those of NK cells transduced with either TIGIT or PD1 chimeric switch receptors alone.
[0144] Example 4
[0145] Put 10 5Individual human ovarian cancer cells (HEY) were incubated in 100 μL of PBS suspension with 0.5 μg of each of the following flow cytometry fluorescent antibodies for 10 minutes in the dark: PE-anti-human PDL1, APC-anti-human PDL2, PE-anti-human CD155, and APC-anti-human CD112. The cells were then washed once with PBS and analyzed by flow cytometry. The results showed that HEY human ovarian cancer cells highly expressed ligands for both TIGIT and PD1 (as shown in Figure 5), suggesting that they could be recognized by the dual-OR chimeric switch receptor. Therefore, the inventors first selected HEY cells for the dual-OR chimeric switch receptor NK cell anti-tumor assay.
[0146] In this example, according to the method of Example 3, the inventors investigated the killing efficiency of NK cells expressing the dual (OR gate) chimeric switch receptor of Example 1 against human ovarian cancer cells HEY.
[0147] The results of the investigation are shown in Figure 6: NK cells transduced with the TIGIT chimeric switch receptor ("TIGIT") or the PD1 chimeric switch receptor ("PD1") killed HEY cells at a higher rate than the control NK cells ("Ctrl"). NK cells transduced with dual (OR-gated) chimeric switch receptors ("TIGIT-PD1" or "PD1-TIGIT") killed HEY cells at a higher rate than the control group, and higher than NK cells transduced with either TIGIT or PD1 chimeric switch receptors alone. The results of this experiment indicate that TIGIT-PD1 or PD1-TIGIT OR-gated chimeric switch receptors can recognize tumor types (such as ovarian cancer) that express TIGIT / PD1 ligands, and may have higher killing efficiency than TIGIT or PD1 chimeric switch receptors alone.
[0148] Furthermore, based on the above effectiveness results, the inventors further identified the anti-tumor ability of NK cells expressing the dual (OR gate) chimeric switch receptor of Example 1 in mice. The specific method is as follows:
[0149] Human ovarian cancer HEY cells were injected subcutaneously into the axilla to establish an ovarian cancer model. Six-week-old immunodeficient non-obese diabetic (NOD)-scidγ mice (NSG) (NOD-SCID mouse background, and IL-2 receptor γ chain deficiency) were selected for subcutaneous tumor bearing. Each mouse was subcutaneously injected with 5×10 6 HEY cells were injected into the tail vein once a week starting from the third day after tumor implantation. 7NK92 cells were administered until the end of the experiment. Starting on the day of the first NK92 cell injection, 50,000 units of interleukin-2 were injected intraperitoneally twice weekly to enhance NK92 cell survival. Tumors were measured weekly for long and short diameters, and tumor volume was calculated to plot tumor growth curves.
[0150] The results of the investigation are shown in Figure 7: Compared with the wild-type NK92 (WT), NK92 cells transduced with the TIGIT chimeric switch receptor ("TIGIT") or the PD1 chimeric switch receptor ("PD1") have a certain therapeutic effect of inhibiting tumor growth. In comparison, NK92 cells transduced with dual (OR gate) chimeric switch receptors ("TIGIT-PD1" or "PD1-TIGIT") have a better therapeutic effect and can inhibit tumor growth to a greater extent (Figure 7). This shows that the dual (OR gate) chimeric switch receptor of the present invention enables NK92 cells to acquire a stronger ability to recognize tumors and activate anti-tumor effector functions.
[0151] Example 5
[0152] In this example, according to the method of Example 3, the inventors investigated the killing efficiency of NK cells expressing the double (OR gate) chimeric switch receptor of Example 1 against human lung cancer HCC827 and NCI-H1975.
[0153] The results are shown in Figures 8 and 9: NK cells transduced with dual (OR-gated) chimeric switch receptors ("TIGIT-PD1" or "PD1-TIGIT") demonstrated higher killing rates against HCC827 and NCI-H1975 cells than the control group. These results demonstrate that TIGIT-PD1 or PD1-TIGIT OR-gated chimeric switch receptors can recognize lung cancer cells and demonstrate high killing efficiency.
[0154] Furthermore, based on the above effectiveness results, the inventors further identified the ability of NK cells expressing the dual (OR gate) chimeric switch receptor of Example 1 to inhibit lung cancer growth in mice. The specific method is as follows:
[0155] Human lung cancer HCC827 cells were injected subcutaneously into the axilla to establish a lung cancer model. Six-week-old immunodeficient non-obese diabetic (NOD)-scidγ mice (NSG) (NOD-SCID mouse background, and IL-2 receptor γ chain deficiency) were selected for subcutaneous tumor bearing. Each mouse was subcutaneously injected with 5×10 6 HCC827 cells were injected into the tail vein once a week starting from the third day after tumor implantation. 7NK92 cells were administered until the end of the experiment. Starting on the day of the first NK92 cell injection, 50,000 units of interleukin-2 were injected intraperitoneally twice weekly to enhance NK92 cell survival. Tumors were measured weekly for long and short diameters, and tumor volume was calculated to plot tumor growth curves.
[0156] The results of the study are shown in Figures 10 and 11: Compared with wild-type NK92 cells (WT), NK92 cells transduced with the dual (OR) chimeric switch receptor ("TIGIT-PD1") exhibited superior therapeutic efficacy and were able to significantly inhibit tumor growth (Figures 10 and 11). This suggests that the dual (OR) chimeric switch receptor of the present invention enables NK92 cells to acquire a stronger ability to recognize tumors and activate anti-tumor effector functions.
[0157] Example 6
[0158] In this example, according to the method of Example 3, the inventors investigated the killing efficiency of NK cells expressing the dual (OR gate) chimeric switch receptor of Example 1 against human esophageal cancer TE-1 and KYSE-150.
[0159] The results are shown in Figures 12 and 13: NK cells transduced with the dual (OR-gated) chimeric switch receptor ("TIGIT-PD1") demonstrated higher killing rates against both TE-1 and KYSE-150 cells than the control group. These results demonstrate that the TIGIT-PD1 OR-gated chimeric switch receptor can recognize esophageal cancer cells and exhibit a high killing efficiency.
[0160] Example 7
[0161] In this example, according to the method of Example 3, the inventors investigated the killing efficiency of NK cells expressing the double (OR gate) chimeric switch receptor of Example 1 against human cervical cancer Hela.
[0162] The results are shown in Figure 14: NK cells transduced with dual (OR-gated) chimeric switch receptors ("TIGIT-PD1" or "PD1-TIGIT") demonstrated a higher killing rate against Hela cells than the control group. This experimental result demonstrates that TIGIT-PD1 or PD1-TIGIT OR-gated chimeric switch receptors can recognize cervical cancer cells and exhibit a high killing efficiency.
[0163] Example 8
[0164] In this example, according to the method of Example 3, the inventors investigated the killing efficiency of NK cells expressing the double (OR gate) chimeric switch receptor of Example 1 against human colorectal cancer HCT15.
[0165] The results are shown in Figure 15: NK cells transduced with a dual (OR-gated) chimeric switch receptor ("TIGIT-PD1") demonstrated a higher killing rate against HCT15 cells than the control group. This experimental result demonstrates that the TIGIT-PD1 OR-gated chimeric switch receptor can recognize colorectal cancer cells and exhibit a high killing efficiency.
[0166] In the description of this specification, the reference terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" mean that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art can combine and combine different embodiments or examples described in this specification and features of different embodiments or examples without contradiction.
[0167] Although the embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and are not to be construed as limitations on the present invention. A person skilled in the art may change, modify, replace and modify the above embodiments within the scope of the present invention.
Claims
1. A chimeric switch receptor, It is characterized in that include: An extracellular region, the extracellular region comprising a first binding fragment and a second binding fragment, the first binding fragment having an amino acid sequence as shown in SEQ ID NO: 10, and the second binding fragment having an amino acid sequence as shown in SEQ ID NO: 11; A transmembrane region, wherein the N-terminus of the transmembrane region is connected to the C-terminus of the extracellular region; The intracellular region has an N-terminus connected to the C-terminus of the transmembrane region.
2. The chimeric switch receptor according to claim 1, It is characterized in that The C-terminus of the first binding fragment is connected to the N-terminus of the second binding fragment, or the N-terminus of the first binding fragment is connected to the C-terminus of the second binding fragment.
3. The chimeric switch receptor according to claim 1, It is characterized in that The extracellular region further includes a connecting peptide; The C-terminus of the first binding fragment is connected to the N-terminus of the connecting peptide, and the C-terminus of the connecting peptide is connected to the N-terminus of the second binding fragment; or The C-terminus of the second binding fragment is connected to the N-terminus of the connecting peptide, and the C-terminus of the connecting peptide is connected to the N-terminus of the first binding fragment.
4. The chimeric switch receptor according to claim 3, It is characterized in that The connecting peptide is selected from (G 4 S) n , ESGRSGGGGSGGGGS, EGKSSGSGSESKST, EGKSSGSGSESKSTQ, GSTSGSGKSSEGKG, KESGS VSSEQ LAQFR SLD, ESGSVSSEELAFRSLD, and n is a non-zero integer.
5. The chimeric switch receptor according to claim 4, It is characterized in that The connecting peptide is selected from (G 4 S) n , n is any integer between 2 and 6.
6. The chimeric switch receptor according to claim 5, It is characterized in that The connecting peptide is (G 4 S) 4 .
7. The chimeric switch receptor according to claim 1, It is characterized in that The extracellular region does not include a Hinge domain.
8. The chimeric switch receptor according to claim 1, It is characterized in that The transmembrane region includes the transmembrane segment of the CD8a molecule.
9. The chimeric switch receptor according to claim 8, It is characterized in that The transmembrane segment of the CD8a molecule has an amino acid sequence as shown in SEQ ID NO:
12.
10. The chimeric switch receptor according to claim 1, It is characterized in that The intracellular region includes a co-stimulatory domain and an intracellular signaling domain; the C-terminus of the co-stimulatory factor domain is connected to the N-terminus of the intracellular signaling domain.
11. The chimeric switch receptor according to claim 10, It is characterized in that The co-stimulatory domain is selected from at least one of CD28, 4-1BB, 2B4, DAP10, DAP12, CD27, CD40, OX40, and ICOS intracellular domains.
12. The chimeric switch receptor according to claim 11, It is characterized in that The co-stimulatory domain is the intracellular segment of the 4-1BB molecule.
13. The chimeric switch receptor according to claim 12, It is characterized in that The intracellular segment of the 4-1BB molecule has an amino acid sequence as shown in SEQ ID NO:
13.
14. The chimeric switch receptor according to claim 10, It is characterized in that The intracellular signal transduction domain is the intracellular segment of the CD3ζ molecule.
15. The chimeric switch receptor according to claim 14, It is characterized in that The intracellular segment of the CD3ζ molecule has an amino acid sequence as shown in SEQ ID NO:
14.
16. The chimeric switch receptor according to claim 1, It is characterized in that The chimeric switch receptor has an amino acid sequence as shown in SEQ ID NO:16 or SEQ ID NO:
27.
17. A nucleic acid molecule, It is characterized in that Encoding the chimeric switch receptor according to any one of claims 1 to 16.
18. An expression vector, It is characterized in that Carrying the nucleic acid molecule of claim 17.
19. The expression vector according to claim 18, It is characterized in that The expression vector is a non-pathogenic viral vector.
20. The expression vector according to claim 19, It is characterized in that The non-pathogenic virus is selected from one of a retrovirus, a lentivirus and an adenovirus-associated virus.
21. A lentiviral vector, It is characterized in that Carrying a nucleotide sequence as shown in SEQ ID NO: 1, SEQ ID NO: 15, SEQ ID NO: 24 or SEQ ID NO:
25.
22. A genetically modified immune cell, It is characterized in that The transgenic immune cells include: Expressing the chimeric switch receptor according to any one of claims 1 to 16; or Carrying the nucleic acid molecule of claim 17, the expression vector of any one of claims 18 to 20, or the lentiviral vector of claim 21.
23. The transgenic immune cell according to claim 22, It is characterized in that The transgenic immune cells are selected from T cells, NK cells, NKT cells, γδT cells, macrophages, peripheral blood NK cells, umbilical cord blood NK cells, NK92 cells, iPSCs or CD34 + At least one of the above-mentioned immune cells is derived from hematopoietic stem cells.
24. The transgenic immune cell according to claim 23, It is characterized in that The transgenic immune cells are selected from NK cells.
25. A pharmaceutical composition, It is characterized in that include: The chimeric switch receptor according to any one of claims 1 to 16, the nucleic acid molecule according to claim 17, the expression vector according to any one of claims 18 to 20, the lentiviral vector according to claim 21, or the transgenic immune cell according to any one of claims 22 to 24.
26. The pharmaceutical composition according to claim 25, It is characterized in that Further including: Pharmaceutically acceptable excipients.
27. Use of the chimeric switch receptor of any one of claims 1 to 16, the nucleic acid molecule of claim 17, the expression vector of any one of claims 18 to 20, the lentiviral vector of claim 21, the transgenic immune cell of any one of claims 22 to 24, or the pharmaceutical composition of any one of claims 25 or 26 in the preparation of a drug for preventing or treating tumors.
28. The use according to claim 27, It is characterized in that The tumor is a solid tumor or a hematological tumor.
29. The use according to claim 28, It is characterized in that The solid tumor includes tangible tumors selected from those occurring in internal organs, including at least one of pancreatic cancer, ovarian cancer, mesothelioma, liver cancer, bile duct cancer, gastric cancer, esophageal cancer, colorectal cancer, lung cancer, head and neck cancer, cervical cancer, glioma, kidney cancer, breast cancer, prostate cancer, thyroid cancer, nasopharyngeal carcinoma, sarcoma, melanoma or squamous cell carcinoma of the skin.
30. The use according to claim 28, It is characterized in that The blood tumor includes at least one selected from acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma, myelodysplastic syndrome or myeloproliferative tumors in blood cells and hematopoietic system.
31. A method for treating and / or preventing immune system diseases, It is characterized in that A pharmaceutically acceptable amount of the transgenic immune cell according to any one of claims 22 to 24 or the pharmaceutical composition according to any one of claims 25 or 26 is administered to a subject.
Citation Information
Patent Citations
Tigit- and light-based chimeric proteins
CN110381983A
Chimeric antigen receptor taking TIGIT and PD-1 as targets, CAR-T cell and preparation method thereof
CN112480264A
Chimeric inhibitory receptors
CN114585371A
Preparation method and application of chimeric transformation receptor gene modified NK (Natural Killer) cell
CN115838439A
Chimeric transformation receptor and application thereof
CN116925236A
